JP2013545724A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545724A5
JP2013545724A5 JP2013531784A JP2013531784A JP2013545724A5 JP 2013545724 A5 JP2013545724 A5 JP 2013545724A5 JP 2013531784 A JP2013531784 A JP 2013531784A JP 2013531784 A JP2013531784 A JP 2013531784A JP 2013545724 A5 JP2013545724 A5 JP 2013545724A5
Authority
JP
Japan
Prior art keywords
seq
sequence
modified polypeptide
gggs
exendin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013531784A
Other languages
English (en)
Japanese (ja)
Other versions
JP6121330B2 (ja
JP2013545724A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/053770 external-priority patent/WO2012050923A2/en
Publication of JP2013545724A publication Critical patent/JP2013545724A/ja
Publication of JP2013545724A5 publication Critical patent/JP2013545724A5/ja
Application granted granted Critical
Publication of JP6121330B2 publication Critical patent/JP6121330B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013531784A 2010-09-28 2011-09-28 作用持続時間が増した改変ポリペプチド Expired - Fee Related JP6121330B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38739110P 2010-09-28 2010-09-28
US61/387,391 2010-09-28
US42208510P 2010-12-10 2010-12-10
US61/422,085 2010-12-10
PCT/US2011/053770 WO2012050923A2 (en) 2010-09-28 2011-09-28 Engineered polypeptides having enhanced duration of action

Publications (3)

Publication Number Publication Date
JP2013545724A JP2013545724A (ja) 2013-12-26
JP2013545724A5 true JP2013545724A5 (https=) 2014-11-06
JP6121330B2 JP6121330B2 (ja) 2017-04-26

Family

ID=44786115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013531784A Expired - Fee Related JP6121330B2 (ja) 2010-09-28 2011-09-28 作用持続時間が増した改変ポリペプチド

Country Status (11)

Country Link
US (2) US9593154B2 (https=)
EP (2) EP3028720A1 (https=)
JP (1) JP6121330B2 (https=)
CN (2) CN106986940A (https=)
BR (1) BR112013007442A2 (https=)
CA (1) CA2812951A1 (https=)
EA (1) EA201390450A1 (https=)
ES (1) ES2563091T3 (https=)
HK (1) HK1225307A1 (https=)
MX (1) MX345245B (https=)
WO (1) WO2012050923A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
HK1208155A1 (en) * 2012-03-28 2016-02-26 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
CA2998528A1 (en) 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
CN108697768B (zh) 2015-12-23 2022-07-22 约翰霍普金斯大学 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
ES2983409T3 (es) * 2016-03-10 2024-10-23 Medimmune Ltd Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
JP7505713B2 (ja) 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント
US20230250147A1 (en) * 2020-07-02 2023-08-10 Sanofi Glp-1r agonistic peptides with reduced activity
CN115925951B (zh) * 2022-11-30 2024-05-24 上海交通大学医学院附属仁济医院 Cd70特异性诊疗一体化分子影像探针的制备方法及应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2672128B1 (fr) 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
DE122007000044I2 (de) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
AU745094B2 (en) 1997-06-13 2002-03-14 Gryphon Sciences Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1054594B1 (en) 1998-02-13 2007-07-04 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
ES2278589T3 (es) 1999-01-14 2007-08-16 Amylin Pharmaceuticals, Inc. Excendinas destinadas a la inhibicion de glucagon.
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
BR0314996A (pt) 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
ATE471340T1 (de) 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CN102977191B (zh) * 2005-11-28 2016-08-10 宾夕法尼亚州大学理事会 有效的c3补体抑制素类似物
EP1976873A2 (en) 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
AU2006341375B2 (en) 2006-03-31 2013-03-21 Amylin Pharmaceuticals, Llc Amylin and amylin agonists for treating psychiatric diseases and disorders
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2007139941A2 (en) 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
EP2046820B1 (en) * 2006-08-01 2010-10-20 Pieris AG Muteins of tear lipocalin and methods for obtaining the same
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP2009003340A (ja) 2007-06-25 2009-01-08 Oki Data Corp 画像形成装置
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2190863B1 (en) * 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
SG189682A1 (en) * 2008-03-31 2013-05-31 Glaxo Group Ltd Drug fusions and conjugates
JP2011523052A (ja) 2008-05-23 2011-08-04 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１受容体アゴニスト・バイオアッセイ
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
EP2398825B1 (en) * 2009-02-19 2017-10-25 Glaxo Group Limited Single variable domain against serum albumin
WO2010120476A2 (en) 2009-04-01 2010-10-21 Amylin Pharmaceuticals, Inc. N-terminus conformationally constrained glp-1 receptor agonist compounds
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
HK1208155A1 (en) * 2012-03-28 2016-02-26 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides

Similar Documents

Publication Publication Date Title
JP2013545724A5 (https=)
JP7739384B2 (ja) グルカゴン及びｇｌｐ－１共アゴニスト化合物
JP2014510518A5 (https=)
CA2893445C (en) Glucagon/glp-1 agonists for the treatment of obesity
ES2646614T3 (es) Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
JP2016512213A5 (https=)
US8450266B2 (en) Analogues of glucose-dependent insulinotropic polypeptide
CN101993496B (zh) 双重调节血糖血脂融合蛋白及其制法和用途
US9714277B2 (en) Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
HRP20191660T1 (hr) Modificirani vezivni proteini koji inhibiraju interakciju receptora vegf-a
JP2013543497A5 (https=)
KR20150131213A (ko) 인슐린-인크레틴 접합체들
WO2010016940A2 (en) Analogues of glucose-dependent insulinotropic polypeptide
WO2016131893A1 (en) Incretin fusion polypeptides
JP2012510803A5 (https=)
JP2015521588A5 (https=)
JP2018533369A5 (https=)
JP2015504052A5 (https=)
JP2014516049A5 (https=)
JP2023116739A5 (https=)
JP2007535910A5 (https=)
AU2017277594A1 (en) Protease-resistant mono-lipidated peptides
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
JP2008522954A5 (https=)
AU2016277449A1 (en) Protease-resistant lipidated GLP-1 analogs